Anuncio • Dec 20

Filament Health Corp. (OTCPK:FLHL.F) cancelled the acquisition of Jupiter Acquisition Corporation (NasdaqCM:JAQC) from a group of shareholders in a reverse merger transaction.

Filament Health Corp. (OTCPK:FLHL.F) entered into a letter of intent to acquire Jupiter Acquisition Corporation (NasdaqCM:JAQC) from a group of shareholders in a reverse merger transaction on June 16, 2023. Filament Health Corp. entered into a definitive agreement to acquire Jupiter Acquisition Corporation from a group of shareholders for approximately $150 million in a reverse merger transaction on July 18, 2023. As part of the acquisition, the parties entered into a business combination to create a new public holding company representing the combined business ("Pubco") that is expected to be listed on Nasdaq. The proposed Business Combination reflects a pro forma enterprise valuation of approximately $210 million, based on certain assumptions. Consideration will be 100% in the form of shares in Pubco, and the proposed Business Combination is expected to provide at least $5 million of net proceeds to Pubco. The proposed Business Combination reflects a pre-money equity value of $176 million for Filament and provides the Filament shareholders and certain other parties a contingent right to receive additional Pubco shares based upon post-closing stock performance. At the closing of the proposed Business Combination, the holders of outstanding Filament shares will receive equity in Pubco valued at $0.85 per share (subject to adjustments). Following the closing, the combined company will be renamed to Filament Health Corp. The proposed business combination is subject to customary closing conditions, including receipt of all regulatory approvals, all waiting periods applicable to the Proposed Business Combination under any Antitrust Law will have expired or been terminated, the Registration Statement will have become effective under the Securities Act, Shares to be issued pursuant to the Proposed Business Combination will have been approved for listing on the NYSE or Nasdaq, as applicable, court orders from the Supreme Court of British Columbia with respect to the Plan of Arrangement, and the approval of the proposed Business Combination by Filament's securityholders and Jupiter's stockholders. The consummation of the proposed business combination is anticipated to occur in the 4th quarter of 2023. The Board of Directors of Filament, having received a unanimous recommendation from the special committee of the Board of Directors (the "Filament Special Committee") in favour of the proposed Business Combination, has determined that the proposed Business Combination is in the best interests of Filament, and resolved to recommend that Filament securityholders vote in favour of the proposed Business Combination (with Mr. Lightburn declaring his interest in the Business Combination and abstaining from the vote of the Board of Directors of Filament). The board of directors of Jupiter has unanimously approved the proposed Business Combination. As of November 13, 2023, Form F-4 registration statement is declared effective. Filament will hold a meeting of its Securityholders on December 11, 2023. As of December 8, 2023, the special meeting will stand adjourned until December 12, 2023, or such other date, time and place to which such meeting may be adjourned or postponed. As of December 11, 2023, the Special Meeting has been adjourned in accordance with the interim order of the Supreme Court of British Columbia made pursuant to the Act in connection with the Arrangement (the "Interim Order"). The adjourned Special Meeting will be reconvened at the offices of Fasken Martineau DuMoulin LLP on December 18, 2023. Evans & Evans, Inc. was appointed as an independent financial advisor to the Filament Special Committee, and provided a fairness opinion to the Filament Special Committee stating that, as of the date of such opinion, and based upon and subject to the assumptions, limitations, and qualifications stated in such opinion, the Business Combination and the consideration payable thereunder is fair from a financial point of view to Filament shareholders. Maxim Group LLC is acting as exclusive financial advisor to Filament. Jon Conlin, Mike Stephens and Shanlee von Vegesack of Fasken Martineau DuMoulin LLP acting as Canadian legal advisors and Barry I. Grossman, Jonathan Deblinger, and Anthony Ain of Ellenoff Grossman & Schole LLP is acting as U.S. legal advisor to Filament. Prentice Durbin and Jeff Sheremeta of Harper Grey LLP acting as Canadian legal advisors and Alan I. Annex, and Brian N. Wheaton of Greenberg Traurig, LLP is acting as U.S. legal advisor to Jupiter. Harper Grey LLP and Greenberg Traurig, LLP acted as due diligence providers to Jupiter. Maxim will receive a cash financial advisory fee at Closing of $1 million. Jupiter retained Newbridge to act as its financial advisor in connection with the Business Combination and to provide an independent fairness opinion to the Jupiter Board. Jupiter agreed to pay Newbridge a fee of $75,000. $10,000 of the fee was paid as a retainer, $35,000 of the fee was paid upon delivery of the opinion, and the remaining $30,000 of the fee is payable upon consummation of the Business Combination. Continental Stock Transfer & Trust Company acted as Jupiter’s transfer agent. Jupiter has engaged Morrow Sodali LLC to assist in the solicitation of proxies for the Special Meeting. Morrow Sodali LLC will receive a fee of approximately $15,000. Filament Health Corp. (OTCPK:FLHL.F) cancelled the acquisition of Jupiter Acquisition Corporation (NasdaqCM:JAQC) from a group of shareholders in a reverse merger transaction on December 18, 2023. Filament Health was required to make material changes to the terms of the Proposed Business Combination and the proposed financing of senior secured convertible notes by Helena Global Investment Opportunities 1 Ltd. (the “Note Financing”) in order to enable the combined company after the Proposed Business Combination to meet Nasdaq listing requirements. Given the material changes required in order to meet Nasdaq listing requirements, the parties have determined not to continue to pursue the Proposed Business Combination and therefore have decided to terminate the Business Combination Agreement. Given that the completion of the Proposed Business Combination is a condition to closing the Note Financing, the Note Financing will not be completed at the present time.

Porcentaje del salario del CEO	n/a
Permanencia del CEO	3.5yrs
Participación del CEO	61.2%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	2.3yrs

Nombre	Posición	Permanencia	Compensación	Propiedad
James Hauslein	Chairman	3.5yrs	sin datos	61.2% $ 38.0m
Gaurav Burman	President & Director	2.3yrs	sin datos	sin datos
Jonathan Leong	Executive Vice President of Strategy and M&A	2.3yrs	sin datos	sin datos
Paul Wagstaff	Special Advisor	no data	sin datos	sin datos
James Harrison	Special Advisor	no data	sin datos	sin datos

Nombre	Posición	Permanencia	Compensación	Propiedad
James Hauslein	Chairman	3.5yrs	sin datos	61.2% $ 38.0m
Gaurav Burman	President & Director	2.3yrs	sin datos	sin datos
George Pita	Independent Director	2.3yrs	sin datos	0.35% $ 217.3k
Robert Knox	Independent Director	2.3yrs	sin datos	0.35% $ 217.3k
John White	Independent Director	2.3yrs	sin datos	0.35% $ 217.3k
James Clarke	Vice Chairman of the Board	2.3yrs	sin datos	sin datos

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2023/12/28 09:36
Precio de las acciones al final del día	2023/12/22 00:00
Beneficios	2023/09/30
Ingresos anuales	2022/12/31

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

This company listing is no longer active

Jupiter Acquisition Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Recent updates

Jupiter Acquisition Corporation Files Form 15

Jupiter Acquisition Corporation(NasdaqCM:JAQC) dropped from NASDAQ Composite Index

Filament Health Corp. (OTCPK:FLHL.F) cancelled the acquisition of Jupiter Acquisition Corporation (NasdaqCM:JAQC) from a group of shareholders in a reverse merger transaction.

Jupiter Acquisition Corporation announced delayed 10-Q filing

Jupiter Acquisition Corporation announced that it has received $5.8 million in funding from Jupiter Founders LLC, Nomura Securities International, Inc., Ladenburg Thalmann & Co. Inc.

Jupiter Acquisition Corporation has completed an IPO in the amount of $150 million.

CEO

Equipo directivo

Miembros de la Junta

Análisis de la empresa y estado de los datos financieros

Fuentes de datos

Modelo de análisis y copo de nieve

Métricas industriales y sectoriales

Fuentes analistas